Abstract: Disclosed are DNA elements and constructs useful for obtaining tumor-selective gene expression in tumors having a mutated ?-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumor cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumor cells can be demonstrated.
Type:
Grant
Filed:
June 26, 2003
Date of Patent:
February 20, 2007
Assignee:
Innovata PLC
Inventors:
Lawrence S. Young, Kai S. Lipinski, Christopher J. Wrighton
Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
Type:
Grant
Filed:
August 6, 2004
Date of Patent:
August 22, 2006
Assignees:
Canji, Inc., Innovata PLC
Inventors:
Susan E. Conroy, Engler Heidrun, Daniel C. Maneval
Abstract: The invention hereindescribed relates to a form of cancer therapy which exploits the cytotoxic properties of acetaminophen when converted to NABQI by the metabolic activity of tumour cell specific P450; vectors for use in the delivery of P450 to tumour cells; and therapeutic compositions comprising said vectors.